Factor VIII gene inversions and polymorphisms in Brazilian patients with haemophilia A: carrier detection and prenatal diagnosis

Haemophilia. 2001 May;7(3):299-305. doi: 10.1046/j.1365-2516.2001.00508.x.

Abstract

In families afflicted with haemophilia A, genetic counselling is often requested. Inversion mutations and polymorphic sites of the FVIII gene have been examined in a Brazilian population, with the aim of developing a strategy that would be accurate and informative for carrier analysis and prenatal diagnosis in Brazil. Patients with haemophilia A and families were studied. Inversion mutations in the FVIII gene were detected in 39.4% of severely affected patients, 85% of them being of distal type. No inversions were observed in patients with mild or moderate forms of the disease. Two bi-allelic polymorphisms were studied. Intron 18 SSCP and intron 19 RFLP analyses indicated the presence of a restriction site in 39.5% and 42.9% of haemophilics, respectively. Two multiallelic microsatellite polymorphisms in introns 13 and 22 were also studied; eight different alleles were detected in each system with a heterozygosity rate of 83.08% and 78.77%, respectively. When all four intragenic loci were examined in linkage analysis, the cumulative reliability was 100%. In conclusion, inversion mutation analysis should be the first-line test for Brazilian patients with severe haemophilia A. In cases of severe haemophilia A where no inversion could be detected or in mild or moderate haemophilia A, the use of all four polymorphisms is very informative for linkage analysis and should be used for carrier detection and genetic counselling in the Brazilian population.

MeSH terms

  • Brazil / epidemiology
  • Chromosome Inversion
  • DNA Mutational Analysis
  • Factor VIII / genetics*
  • Family Health
  • Female
  • Gene Frequency
  • Genetic Carrier Screening / methods
  • Genetic Testing
  • Hemophilia A / genetics*
  • Humans
  • Introns
  • Male
  • Polymorphism, Genetic
  • Prenatal Diagnosis / methods

Substances

  • Factor VIII